Emergent Biosolutions Inc (NYSE:EBS) Shares Sold by Hodges Capital Management Inc.

Hodges Capital Management Inc. cut its holdings in Emergent Biosolutions Inc (NYSE:EBS) by 76.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,847 shares of the biopharmaceutical company’s stock after selling 50,815 shares during the quarter. Hodges Capital Management Inc.’s holdings in Emergent Biosolutions were worth $1,637,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. Nuveen Asset Management LLC raised its holdings in Emergent Biosolutions by 13.4% during the 1st quarter. Nuveen Asset Management LLC now owns 266,796 shares of the biopharmaceutical company’s stock worth $15,437,000 after buying an additional 31,481 shares during the period. Legal & General Group Plc raised its holdings in Emergent Biosolutions by 0.3% during the 1st quarter. Legal & General Group Plc now owns 136,848 shares of the biopharmaceutical company’s stock worth $7,903,000 after buying an additional 373 shares during the period. Geode Capital Management LLC raised its holdings in Emergent Biosolutions by 6.6% during the 1st quarter. Geode Capital Management LLC now owns 641,292 shares of the biopharmaceutical company’s stock worth $37,104,000 after buying an additional 39,965 shares during the period. Wells Fargo & Company MN raised its holdings in Emergent Biosolutions by 51.0% during the 1st quarter. Wells Fargo & Company MN now owns 469,227 shares of the biopharmaceutical company’s stock worth $27,150,000 after buying an additional 158,422 shares during the period. Finally, Thrivent Financial for Lutherans raised its holdings in Emergent Biosolutions by 5.3% during the 1st quarter. Thrivent Financial for Lutherans now owns 36,776 shares of the biopharmaceutical company’s stock worth $2,128,000 after buying an additional 1,836 shares during the period.

NYSE:EBS opened at $98.88 on Friday. Emergent Biosolutions Inc has a 1-year low of $46.37 and a 1-year high of $137.61. The company has a current ratio of 2.71, a quick ratio of 1.91 and a debt-to-equity ratio of 0.63. The firm has a fifty day simple moving average of $104.85 and a 200 day simple moving average of $90.81. The stock has a market capitalization of $5.23 billion, a PE ratio of 30.80 and a beta of 1.40.

Emergent Biosolutions (NYSE:EBS) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.98 earnings per share for the quarter, beating the consensus estimate of $0.53 by $1.45. Emergent Biosolutions had a net margin of 13.52% and a return on equity of 22.92%. The business had revenue of $394.70 million during the quarter. On average, equities analysts predict that Emergent Biosolutions Inc will post 6.61 earnings per share for the current fiscal year.

In other Emergent Biosolutions news, Director George A. Joulwan sold 6,000 shares of Emergent Biosolutions stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $124.11, for a total transaction of $744,660.00. Following the completion of the transaction, the director now directly owns 26,771 shares of the company’s stock, valued at $3,322,548.81. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Zsolt Harsanyi sold 6,609 shares of Emergent Biosolutions stock in a transaction on Monday, August 17th. The stock was sold at an average price of $133.71, for a total transaction of $883,689.39. Following the transaction, the director now directly owns 24,579 shares of the company’s stock, valued at $3,286,458.09. The disclosure for this sale can be found here. Insiders sold 126,562 shares of company stock valued at $13,494,405 over the last three months. 14.10% of the stock is owned by company insiders.

EBS has been the topic of several research analyst reports. ValuEngine downgraded shares of Emergent Biosolutions from a “hold” rating to a “sell” rating in a report on Wednesday, September 16th. Wells Fargo & Company raised their price target on shares of Emergent Biosolutions from $85.00 to $93.00 and gave the stock an “overweight” rating in a research note on Thursday, July 2nd. Cantor Fitzgerald raised their price target on shares of Emergent Biosolutions from $85.00 to $110.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. JPMorgan Chase & Co. began coverage on shares of Emergent Biosolutions in a research note on Monday, September 14th. They set a “neutral” rating for the company. Finally, Chardan Capital raised their price target on shares of Emergent Biosolutions from $86.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $92.57.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.

See Also: Why are trading ranges significant?

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.